Recent advances in dermal wound healing: Biomedical device approaches

Expert Review of Medical Devices

Volumn 7, Issue 1, 2010, Pages 143-154

  Rizzi, Simone C ^a,b   Upton, Zee ^a   Bott, Katrin ^c   Dargaville, Tim R ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b EPFL   (Switzerland)

^c ZEDIRA GMBH   (Germany)

Author keywords

Chronic wound; Device; Growth factor; Scaffold; Skin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; BIOMEDICAL AND DENTAL MATERIALS; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SILICONE; UNCLASSIFIED DRUG; VITROGRO; WOUND HEALING PROMOTING AGENT; TISSUE SCAFFOLD;

ACELLULAR DERMAL MATRIX; BURN; CAREGIVER BURDEN; CELL COMMUNICATION; CHRONIC WOUND; COST BENEFIT ANALYSIS; DRUG CONTROL; DRUG EFFICACY; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; HYDROGEL; NONHUMAN; PAIN; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; REVIEW; SCAR FORMATION; SKIN GRAFT; SKIN INJURY; SKIN SCAR; SKIN SUBSTITUTE; SKIN TRANSPLANTATION; SKIN ULCER; TISSUE ENGINEERING; TISSUE REPAIR; WOUND CARE; WOUND DRESSING; WOUND HEALING; XENOGRAFT; ANIMAL; ARTIFICIAL SKIN; CHRONIC DISEASE; DERMIS; INJURY;

ANIMALS; CHRONIC DISEASE; DERMIS; HUMANS; SKIN, ARTIFICIAL; TISSUE SCAFFOLDS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 77449160074     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.57     Document Type: Review

References (88)

1. Boyce ST, Warden GD. Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am. J. Surg. 183(4), 445-456 (2002).
2. Phillips TJ. Current approaches to venous ulcers and compression. Dermatol. Surg. 27(7), 611-621 (2001).
3. Sweitzer SM, Fann SA, Borg TK, Baynes J W, Yost MJ. What is the future of diabetic wound care? Diabetes Educ. 32(2), 197-210 (2006). (Pubitemid 43472149)
4. Clark RA. Fibrin and wound healing. Ann. NY Acad. Sci. 936, 355-367 (2001).
5. Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 12(9), 2407-2424 (2006). (Pubitemid 46150659)
6. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature 445(7130), 874-880 (2007). (Pubitemid 46315824)
7. Martin P. Wound healing-aiming for perfect skin regeneration. Science 276(5309), 75-81 (1997). (Pubitemid 27161246)
8. Hrabchak C, Flynn L, Woodhouse KA. Biological skin substitutes for wound cover and closure. Expert Rev. Med. Devices 3(3), 373-385 (2006).
9. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J. Invest. Dermatol. 127(5), 1018-1029 (2007). (Pubitemid 46625159)
10. Gosh K, Clark RAF. Wound repair: basic biology of tissue engineering. In: Principles of Tissue Engineering (3rd edition). Lanza A, Langer R, Vacanti JP (Eds). Elsevier/Academic Press, Amsterdam, The Netherlands (2007).
11. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv. Skin Wound Care 17(1), 24-35 (2004).
12. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91(4), 439-442 (1997). (Pubitemid 27508232)
13. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23(1), 47-55 (2005).
14. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516 (2001). (Pubitemid 33096184)
15. Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface 4(14), 413-437 (2007).
16. Greenhalgh DG. Consequences of excessive scar formation: dealing with the problem and aiming for the future. Wound Repair Regen. 15, S2-S5 (2007).
17. Kose O, Waseem A. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol. Surg. 34(3), 336-346 (2008). (Pubitemid 351316825)
18. Bayat A, McGrouther DA, Ferguson MWJ. Skin scarring. Br. Med. J. 326(7380), 88-92 (2003). (Pubitemid 36092292)
19. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today 4(1), 19-24 (1998).
20. Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 15, S6-S17 (2007). (Pubitemid 47301668)
21. Ferguson MWJ, Oi'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 359(1445), 839-850 (2004).
22. Ghahary A, Shen YJ, Nedelec B, Wang RJ, Scott PG, Tredget EE. Collagenase production is lower in post-burn hypertrophic scar fbroblasts than in normal fbroblasts and is reduced by insulin-like growth factor-1. J. Invest. Dermatol. 106(3), 476-481 (1996). (Pubitemid 26117584)
23. Kloeters O, Tandara A, Mustoe TA. Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction. Wound Repair Regen. 15, S40-S45 (2007). (Pubitemid 47301673)
24. Liang Z, Engrav LH, Muangman P et al. Nerve quantifcation in female red Duroc pig (FRDP) scar compared with human hypertrophic scar. Burns 30(1), 57-64 (2004). (Pubitemid 38029125)
25. Phillips TJ. New skin for old: developments in biological skin substitutes. Arch. Dermatol. 134(3), 344-349 (1998). (Pubitemid 28141622)
26. Singer AJ, Clark RA. Cutaneous wound healing. N. Engl. J. Med. 341(10), 738-746 (1999).
27. Hutmacher DW, Ng KW, Khor HL. Skin tissue engineering Part 1-review. In: Biodegradable Systems in Tissue Engineering and Regenerative Medicine. Reis RL, Romin JS (Eds). Routledge, NY, USA, 509-528 (2004).
28. Steed DL, Donohoe D, Webster MW, Lindsley L; Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J. Am. Coll. Surg. 183(1), 61-64 (1996). (Pubitemid 26234895)
29. Brem H, Sheehan P, Boulton AJ. Protocol for treatment of diabetic foot ulcers. Am. J. Surg. 187(5A), S1-S10 (2004). (Pubitemid 38625981)
30. Griffths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. Tissue Eng. 10(7-8), 1180-1195 (2004). (Pubitemid 39223796)
31. Omar AA, Mavor AI, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur. J. Vasc. Endovasc. Surg. 27(6), 666-672 (2004). (Pubitemid 38635012)
32. Phillips TJ, Manzoor J, Rojas A et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch. Dermatol. 138(8), 1079-1081 (2002). (Pubitemid 34875612)
33. Wisser D, Steffes J. Skin replacement with a collagen based dermal substitute, autologous keratinocytes and fbroblasts in burn trauma. Burns 29(4), 375-380 (2003). (Pubitemid 36627682)
34. Falanga V, Margolis D, Alvarez O et al.; Human Skin Equivalent Investigators Group. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch. Dermatol. 134(3), 293-300 (1998). (Pubitemid 28141616)
35. Nunery WR. Risk of prion transmission with the use of xenografts and allografts in surgery. Ophthal. Plast. Reconstr. Surg. 17(6), 389-394 (2001).
36. Jones I, Currie L, Martin R. A guide to biological skin substitutes. Br. J. Plast. Surg. 55(3), 185-193 (2002). (Pubitemid 34591356)
37. Greenleaf G, Hansbrough JF. Current trends in the use of allograft skin for patients with burns and refections on the future of skin banking in the United States. J. Burn Care Rehabil. 15(5), 428-431 (1994). (Pubitemid 24289542)
38. Hodde JP, Johnson CE. Extracellular matrix as a strategy for treating chronic wounds. Am. J. Clin Dermatol. 8(2), 61-66 (2007).
39. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J. Vasc. Surg. 41(5), 837-843 (2005). (Pubitemid 40693807)
40. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv. Skin Wound Care 18(5 Pt 1), 258-266 (2005).
41. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 16(5), 585-601 (2008).
42. Giancotti FG, Ruoslahti E. Integrin signaling. Science 285(5430), 1028-1032 (1999). (Pubitemid 129515440)
43. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 24(3), 483-488 (2001). (Pubitemid 32198417)
44. Fu X, Li X, Cheng B, Chen W, Sheng Z. Engineered growth factors and cutaneous wound healing: success and possible questions in the past 10 years. Wound Repair Regen. 13(2), 122-130 (2005). (Pubitemid 40489861)
45. Upton Z, Cuttle L, Noble A et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J. Invest. Dermatol. 128(6), 1535-1544 (2008). (Pubitemid 351693179)
46. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144(7), 2807-2815 (2003). (Pubitemid 36819880)
47. Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-kinase/AKT pathway by av-integrins and the IGF-I receptor. Endocrinology 149(3), 1075-1090 (2008). (Pubitemid 351397938)
48. Van Lonkhuyzen DR, Hollier BG, Shooter GK, Leavesley DI, Upton Z. Chimeric vitronectin:insulin-like growth factor proteins enhance cell growth and migration through co-activation of receptors. Growth Factors 25(5), 295-308 (2007). (Pubitemid 351194028)
49. Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res. 15, 66-71 (2005). (Pubitemid 41653969)
50. Ehrbar M, Djonov VG, Schnell C et al. Cell-demanded liberation of VEGF121 from fbrin implants induces local and controlled blood vessel growth. Circ. Res. 94(8), 1124-1132 (2004). (Pubitemid 38579708)
51. Sakiyama-Elbert SE, Panitch A, Hubbell JA. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15(7), 1300-1302 (2001).
52. Schmoekel HG, Weber FE, Schense JC, Gratz K W, Schawalder P, Hubbell JA. Bone repair with a form of BMP-2 engineered for incorporation into fbrin cell ingrowth matrices. Biotechnol. Bioeng. 89(3), 253-262 (2005). (Pubitemid 40288876)
53. Schense JC, Hubbell JA. Cross-linking exogenous bifunctional peptides into fbrin gels with factor XIIIa. Bioconjug. Chem. 10(1), 75-81 (1999).
54. Lehnhardt M, Hauser J, Daigeler A et al. The use of a variant PDGF incorporated into fbrin sealant in burn patients undergoing autologous meshed skin grafting: a Phase 2a clinical study. Wound Repair Regen. 17(2), A13 (2009).
55. ®, an advanced wound treatment for venous ulcers: a European perspective. Wounds UK 4(1), 106-110 (2008). (Pubitemid 351548148)
56. Rosso F, Marino G, Giordano A, Barbarisi M, Parmeggiani D, Barbarisi A. Smart materials as scaffolds for tissue engineering. J. Cell Physiol. 203(3), 465-470 (2005). (Pubitemid 40629007)
57. Fedorovich NE, Alblas J, de Wijn JR, Hennink WE, Verbout AJ, Dhert WJ. Hydrogels as extracellular matrices for skeletal tissue engineering: state-of-the-art and novel application in organ printing. Tissue Eng. 13(8), 1905-1925 (2007). (Pubitemid 47293990)
58. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 428(6982), 487-492 (2004). (Pubitemid 38480528)
59. Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng. Part B Rev. 14(2), 149-165 (2008). (Pubitemid 351839212)
60. Winter GD. Formation of the scab and the rate of epithelization of superfcial wounds in the skin of the young domestic pig. Nature 193, 293-294 (1962).
61. Cushing MC, Anseth KS. Materials science. Hydrogel cell cultures. Science 316(5828), 1133-1134 (2007).
62. Ehrbar M, Rizzi SC, Hlushchuk R et al. Enzymatic formation of modular cell-instructive fbrin analogs for tissue engineering. Biomaterials 28(26), 3856-3866 (2007). (Pubitemid 47048348)
63. Shu XZ, Ghosh K, Liu Y et al. Attachment and spreading of fbroblasts on an RGD peptide-modifed injectable hyaluronan hydrogel. J. Biomed. Mater. Res. A 68(2), 365-375 (2004). (Pubitemid 38524731)
64. Ghosh K, Ren XD, Shu XZ, Prestwich GD, Clark RA. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fbroblast responses critical for wound healing. Tissue Eng. 12(3), 601-613 (2006). (Pubitemid 43673465)
65. Serban MA, Liu Y, Prestwich GD. Effects of extracellular matrix analogues on primary human fbroblast behavior. Acta Biomater. 4(1), 67-75 (2008). (Pubitemid 350131566)
66. Schneider A, Garlick JA, Egles C. Self-assembling peptide nanofber scaffolds accelerate wound healing. PLoS ONE 3(1), e1410 (2008). (Pubitemid 351234508)
67. Gelain F, Horii A, Zhang S. Designer self-assembling peptide scaffolds for 3-D tissue cell cultures and regenerative medicine. Macromol. Biosci. 7(5), 544-551 (2007). (Pubitemid 47264628)
68. Ehrbar M, Rizzi SC, Schoenmakers RG et al. Biomolecular hydrogels formed and degraded via site-specifc enzymatic reactions. Biomacromolecules 8(10), 3000-3007 (2007). (Pubitemid 350011618)
69. Rizzi SC, Xie Y, Dawson R et al. Injectable biomimetic matrices to guide impaired wound healing. Wound Repair Regen. 16(4), A62-A63 (2008).
70. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 453(7193), 314-321 (2008). (Pubitemid 351693137)
71. Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast. Surg. 31(5), 468-492 (2007). (Pubitemid 47437506)
72. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J. Am. Coll. Surg. 206(4), 719-730 (2008).
73. Li-Tsang CWP, Lau JCM, Choi J, Chan CCC, Jianan L. A prospective randomized clinical trial to investigate the effect of silicone gel sheeting (Cica-Care) on post-traumatic hypertrophic scar among the Chinese population. Burns 32(6), 678-683 (2006). (Pubitemid 44293058)
74. Chernoff WG, Cramer H, Su-Huang S. The effcacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic Plast. Surg. 31(5), 495-500 (2007). (Pubitemid 47437499)
75. Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast. Surg. 32(1), 82-92 (2008).
76. Berman B, Perez OA, Konda S et al. A review of the biologic effects, clinical effcacy, and safety of silicone elastomer sheeting for hypertrophic and keloid scar treatment and management. Dermatol. Surg. 33(11), 1291-1303 (2007). (Pubitemid 47624077)
77. Occleston NL, Oi'Kane S, Goldspink N, Ferguson MWJ. New therapeutics for the prevention and reduction of scarring. Drug Discovery Today 13(21-22), 973-981 (2008).
78. Niessen FB, Spauwen PHM, Robinson PH, Fidler V, Kon M. The use of silicone occlusive sheeting (Sil-K) and silicone occlusive gel (epiderm) in the prevention of hypertrophic scar formation. Plast. Reconstr. Surg. 102(6), 1962-1972 (1998). (Pubitemid 28518520)
79. Gold MH, Foster TD, Adair MA, Burlison K, Lewis T. Prevention of hypertrophic scars and keloids by the prophylactic use of topical silicone gel sheets following a surgical procedure in an offce setting. Dermatol. Surg. 27(7), 641-644 (2001). (Pubitemid 32652393)
80. Oi'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst. Rev. (1), CD003826 (2006).
81. Shah M, Foreman D, Ferguson M. Neutralization of TGF-b(1) and TGF-b(2) or exogenous addition of TGF-b(3) to cutaneous rat wounds reduces scarring. J. Cell Sci. 108, 985-1002 (1995).
82. Occleston NL, Laverty HG, Oi'Kane S, Ferguson MWJ. Prevention and reduction of scarring in the skin by transforming growth factor b 3 (TGF b3): from laboratory discovery to clinical pharmaceutical. J. Biomater. Sci. Polym. Ed. 19(8), 1047-1063 (2008).
83. Hamrell MR. An overview of the US regulatory environment for drug-device and biologic-device combination products. Drug Inf. J. 40(1), 23-32 (2006).
84. McGuckin M, Waterman R, Brooks J et al. Validation of venous leg ulcer guidelines in the United States and United Kingdom. American J. Surgery 183(2), 132-137 (2002). (Pubitemid 34246423)
85. Herdrich BJ, Lind RC, Liechty KW. Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy 10(6), 543-550 (2008).
86. Zhu N, Warner RM, Simpson C et al. Treatment of burns and chronic wounds using a new cell transfer dressing for delivery of autologous keratinocytes. European J. Plastic Surgery 28, 319-330 (2005). (Pubitemid 43055202)
87. Wieman TJ, Smiell JM, Su Y. Effcacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study. Diabetes Care 21(5), 822-827 (1998). (Pubitemid 28487079)
88. Fu X, Shen Z, Chen Y et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fbroblast growth factor for second-degree burns. Lancet 352(9141), 1661-1664 (1998). (Pubitemid 28526124)